Prolonged Grief Disorder Is Now a Diagnosis. Most Clinicians Cannot Name the Criteria.

Two diagnostic manuals. Two separate committees. The same conclusion: prolonged grief disorder is a real, distinct clinical entity that warrants its own diagnostic code. ICD-11 included it in 2019. DSM-5-TR followed in 2022. And yet, if you stopped ten mental health professionals in a hospital corridor and asked them to list the diagnostic criteria, most would fail. Killikelly and colleagues have written what amounts to a crash course for the field — a Lancet clinical seminar that compresses years of accumulated evidence into a single, densely practical resource.

The diagnostic landscape

The two systems agree on the core construct but differ in specifics. ICD-11 requires persistent preoccupation with or yearning for the deceased, accompanied by intense emotional pain — symptoms that must persist beyond a culturally normative period, cause significant functional impairment, and exceed what is expected given the social and cultural context. The time threshold is deliberately left flexible. DSM-5-TR is more prescriptive: it specifies a minimum of 12 months since the death and requires at least three of eight additional symptoms (identity disruption, disbelief, avoidance, intense emotional pain, difficulty reintegrating, emotional numbness, meaninglessness, intense loneliness).

This is not a trivial difference. A clinician trained exclusively on ICD-11 criteria might identify PGD at 8 months post-loss in a cultural context where 6 months is normative. The same presentation would not qualify under DSM-5-TR until month 12. Understanding both systems is not academic. It determines when intervention begins.

Who develops PGD

The 10% prevalence figure is not uniform. It is shaped by the nature of the loss and the person who lost. Violent death — homicide, suicide, accident — elevates risk substantially. So does the loss of a child, regardless of the child's age. Pre-existing psychiatric conditions, particularly depression and anxiety disorders, function as vulnerability factors. Insecure attachment style predisposes to prolonged grief through the same mechanism it disrupts all significant loss: the internal working model cannot update. The deceased remains present in the attachment system long after they are absent from the world.

Cultural context modulates everything. What looks like pathological preoccupation in one cultural framework may be normative mourning behavior in another. The Lancet seminar is explicit about this: clinicians must assess grief symptoms against the backdrop of the individual's cultural, religious, and social expectations — not against a Western psychiatric default. This is not cultural relativism. It is diagnostic precision.

Treatment evidence

Psychotherapy works. Specifically, two approaches have accumulated meaningful evidence. Prolonged Grief Disorder Therapy (PGDT), developed by Shear and colleagues, integrates elements of interpersonal therapy and CBT within a dual-process framework — simultaneously addressing loss-oriented processing (confronting the reality and pain of the death) and restoration-oriented processing (rebuilding a functional life). Grief-focused CBT targets the cognitive mechanisms that maintain prolonged grief: negative appraisals of the loss and its consequences, avoidance of grief-related stimuli, and depressogenic rumination.

Pharmacotherapy tells a less encouraging story. SSRIs do not reliably reduce prolonged grief symptoms as a primary outcome — though they may help with comorbid depression. There is preliminary evidence for some benefit from naltrexone and ketamine, but the data are insufficient for clinical recommendations. The seminar is careful here: medication may support psychotherapy but should not replace it.

What gets missed

The most clinically consequential finding in this review is not about treatment. It is about recognition. The majority of individuals with PGD are never identified, never assessed with validated instruments, and never referred for grief-specific intervention. They present with depression, anxiety, insomnia, somatic complaints — and receive generic treatments for those presenting problems. The grief goes unaddressed because no one asks the right questions.

Validated screening tools exist. The International Prolonged Grief Disorder Scale (IPGDS), the Prolonged Grief-13 (PG-13), and the Brief Grief Questionnaire can all be administered in under ten minutes. The barrier is not the tools. It is the clinical habit of not using them.

Clinical bottom line

If you work with bereaved patients — and nearly every clinician does — learn the diagnostic criteria for PGD in whichever system you use. Screen for it. Ask about yearning, preoccupation, and functional impairment at 6 and 12 months post-loss. When you identify PGD, refer for or deliver grief-specific psychotherapy — not generic CBT for depression, not medication alone. This Lancet seminar is the single most efficient way to get current on a diagnosis that most of us should have learned years ago. Read it. The 10% of your bereaved patients who develop PGD are waiting for you to recognize what they cannot articulate.